SCHEMBL10061697

SCHEMBL10061697

CCNc1ncnc2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.67
LMNA P02545 4/20 0.67
S1PR2 O95136 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
EGFR P00533 5/20 0.65
NR2F2 P24468 3/20 0.65
RAB9A P51151 3/20 0.65
GALR3 O60755 2/20 0.65
LDHA P00338 1/20 0.64
HTT P42858 5/20 0.63
GAA P10253 3/20 0.63
KMT2A Q03164 3/20 0.63
MAPK1 P28482 2/20 0.63
MEN1 O00255 2/20 0.63
MAPT P10636 2/20 0.63
TSHR P16473 1/20 0.63
ALPG P10696 1/20 0.62
APP P05067 1/20 0.61
POLB P06746 1/20 0.57
ALDH1A1 P00352 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluorobenzene SCHEMBL27970002 0.91 EGFR (0.59) SMN1; SMN2LMNAS1PR2NPSR1EGFR
SCHEMBL12199178 0.86 SMN1; SMN2 (0.77) SMN1; SMN2LMNAS1PR2NPSR1EGFR
SCHEMBL170193 0.82 LMNA (0.97) SMN1; SMN2LMNAS1PR2NPSR1EGFR
SCHEMBL16259077 0.81 EGFR (0.59) SMN1; SMN2LMNAS1PR2NPSR1EGFR
Hydrochloric Acid SCHEMBL8522254 0.80 SMN1; SMN2 (0.94) SMN1; SMN2LMNAS1PR2NPSR1EGFR
SCHEMBL15922842 0.80 LMNA (1.00) SMN1; SMN2LMNAS1PR2NPSR1EGFR
SCHEMBL31197370 0.80 LMNA (1.00) SMN1; SMN2LMNAS1PR2NPSR1EGFR
SCHEMBL15923566 0.80 LMNA (1.00) SMN1; SMN2LMNAS1PR2NPSR1EGFR
SCHEMBL11261445 0.79 SMN1; SMN2 (0.63) SMN1; SMN2LMNAS1PR2NPSR1EGFR
SCHEMBL11244483 0.79 LDHA (0.74) SMN1; SMN2LMNAS1PR2NPSR1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115362003-B Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-03-22 CN disclosed
US-20230159446-A1 Methods and Compositions for Targeting Tregs using CCR8 Inhibitors NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) 2023-05-25 US disclosed
US-20230038589-A1 Methods and compositions for targeting Tregs using CCR8 inhibitors Nanjing Immunophage Biotech Co., Ltd. (CN) 2023-02-09 US disclosed
WO-2012027495-A1 PIPERAZINYLPYRIMIDINE ANALOGUES AS PROTEIN KINASE INHIBITORS UNIVERSITY OF THE PACIFIC (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159446-A1 Methods and Compositions for Targeting Tregs using CCR8 Inhibitors CCR8, CCR1, CCR3 SMN1; SMN2 4731/4885LMNA 4214/4885S1PR2 455/4885
US-20230038589-A1 Methods and compositions for targeting Tregs using CCR8 inhibitors CCR8, CCR1, CCR3 SMN1; SMN2 4731/4885LMNA 4214/4885S1PR2 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.